Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Novus Therapeutics, Inc.

    Client Virtual Booth

    NOVUS THERAPEUTICS, INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Novus Therapeutics, Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    19900 MacArthur Blvd., Suite 550 Irvine, California 92612, USA
    Telephone
    Telephone
    +1 949-238-8090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://novustherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/novustherapeutics/?originalSubdomain=in
    Twitter
    Twitter
    https://twitter.com/NovusThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novus Therapeutics Enrolled First Patient in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

    Details:

    The AT-1501 Phase 2a trial in ALS is an open label, dose escalating, safety and biomarker study. AT-1501 blocks activation of the CD40L pathway, that has been seen to improve muscle function, slow disease progression, and improve survival in a pre-clinical animal model.


    Lead Product(s): AT-1501

    Therapeutic Area: Neurology Product Name: AT-1501

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 02, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

    Details:

    Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.


    Lead Product(s): AT-1501

    Therapeutic Area: Neurology Product Name: AT-1501

    Highest Development Status: Phase IIProduct Type: Large molecule

    Recipient: Anelixis Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition September 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media

    Details:

    Although the study did not achieve statistical significance for the primary efficacy endpoints, But the statistical trend were encouraging that favored the OP0201 treatment group with regard to resolution of middle ear effusion.


    Lead Product(s): DPPC,Cholesteryl Palmitate

    Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

    Details:

    Study is assessing the safety, tolerability, and efficacy of 20 mg/day intranasal OP0201 as an adjunct therapy to oral antibiotic treatment of acute otitis media in infants and 6 to 24 months olds.


    Lead Product(s): DPPC,Cholesteryl Palmitate

    Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 02, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search